Myriad Genetics Investors: Filing Deadline in MYGN Class Action – Contact Lieff Cabraser

Myriad Genetics Inc., Securities Class Litigation

SAN FRANCISCO, CA – (October 10, 2019) – The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that securities fraud class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) between September 2, 2016 and August 13, 2019, inclusive (the “Class Period”). [Read more…]